MP79-19 IMPACT OF INTRINSIC AND EXTRINSIC FACTORS ON THE DETECTION RATE OF THE PET TRACER FLUCICLOVINE (18F) IN BIOCHEMICAL RELAPSE OF PROSTATE CANCER: A MULTI-INSTITUTIONAL EXPERIENCE

Attempts to predict the likelihood of positive morphological imaging related with PSA value in patients referred with biochemical recurrence were the focus of many studies. Using nuclear medicine modalities, numerous studies likewise had been performed for the same purpose, however mostly using C-11-labeled choline. For this purpose, we selected 193 prostate cancer patients from our database between 2006 and 2010. They had been referred to our department to undergo 18F-fluorethylcholine (FECH)-PET/CT due to biochemical recurrence after potentially curative procedures. As a result, in 84 out of 193 patients, 18F-FECH-PET demonstrated positive findings with an overall detection rate of 44%. Statistically, there was a significant difference in PSA values in positive findings vs. negative findings (p<0.001), and there was a linear correlation between the detection rate and PSA value (r = 0.91). Moreover, there was a relation between initial therapy and recurrence type. So, the local relapse was the most frequent recurrence (>70%) after radiation therapy alone. By contrast, patients after radical prostatectomy followed by salvage radiotherapy showed a low likelihood of local recurrence. In conclusion, PSA value was confirmed to have a determinant role in 18F-FECH-PET outcome. Moreover, there was a link between recurrence type and initial therapy, which—if prospectively confirmed—may play a guiding role in selecting the appropriate diagnostic methods.

Download Full-text

Differences in Distribution and Detection Rate of the [68Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer

Pharmaceuticals ◽

10.3390/ph15010009 ◽

2021 ◽

Vol 15 (1) ◽

pp. 9

Author(s):

Falk Gühne ◽

Stefanie Radke ◽

Thomas Winkens ◽

Christian Kühnel ◽

Julia Greiser ◽

...

Keyword(s):

Prostate Cancer ◽

Detection Rate ◽

Blood Pool ◽

Diagnostic Methods ◽

Patient Treatment ◽

Biochemical Relapse ◽

Tumor Lesion ◽

Individual Comparison ◽

Tracer Accumulation ◽

Tumor Detection Rate

The biochemical relapse of prostate cancer is diagnostically challenging but of high clinical impact for subsequent patient treatment. PET/CT with radiolabeled PSMA ligands outperforms conventional diagnostic methods in the detection of tumor recurrence. Several radiopharmaceuticals were and are available for use. The aim of this study was to investigate whether the routinely applied [68Ga]Ga-PSMA ligands PSMA-617, -I&T and -11 (HBED-CC) differ in physiological and pathological distribution, or in tumor detection rate. A retrospective evaluation of 190 patients (39 patients received PSMA-617, 68 patients PSMA-I&T and 83 patients PSMA-11) showed significant differences in tracer accumulation within all organs examined. The low retention within the compartments blood pool, bone and muscle tissue is a theoretical advantage of PSMA-11. Evaluation of tumor lesion uptake and detection rate did not reveal superiority of one of the three radiopharmaceuticals, neither in the whole population, nor in particularly challenging subgroups like patients with very low PSA levels. We conclude that all three [68Ga]Ga-PSMA ligands are equally feasible in this clinically important scenario, and may replace each other in case of unavailability or production restrictions.

Download Full-text

685: Financial Comparative Analysis of Cryosurgical Ablation of the Prostate and Surgical Prostatectomy for Clinically Localized Prostate Cancer: Single Institutional Experience

The Journal of Urology ◽

10.1016/s0022-5347(18)32931-8 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 222-222

Author(s):

Vladimir Mouraviev ◽

Israel Nosnik ◽

Thomas J. Polascik

Keyword(s):

Prostate Cancer ◽

Comparative Analysis ◽

Localized Prostate Cancer ◽

Institutional Experience ◽

Cryosurgical Ablation

Download Full-text

1962: Correlation between Prostate Cancer Detection Rate and Gland Volume: Is Increased Biopsy Sampling Needed for Patients with a Large Prostate?

The Journal of Urology ◽

10.1016/s0022-5347(18)32122-0 ◽

2007 ◽

Vol 177 (4S) ◽

pp. 651-651

Author(s):

Nicolas B. Delongchamps ◽

Vishal Chandan ◽

Richard Jones ◽

Gregory Threatte ◽

Mary Jumbelic ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Detection ◽

Detection Rate ◽

Cancer Detection Rate ◽

Prostate Cancer Detection ◽

Gland Volume ◽

Large Prostate

Download Full-text

1811: Multiplanar Ultrasound Probes Enhance Prostate Cancer Detection Rate in Tic-Patients

The Journal of Urology ◽

10.1016/s0022-5347(18)39003-7 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 479-479

Author(s):

Roger Paul ◽

Christian Korzineck ◽

Ulrike Necknig ◽

Herbert Leyh ◽

Thomas Niesel ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Detection ◽

Detection Rate ◽

Cancer Detection Rate ◽

Prostate Cancer Detection ◽

Ultrasound Probes

Download Full-text

Detection rate of Tc-99 m-PSMA I&S SPECT/CT in comparison to Ga-68-PSMA PET/CT in patients with biochemically recurrent prostate cancer planned for radioguided surgery

10.1055/s-0039-1683604 ◽

2019 ◽

Author(s):

C Berliner ◽

M Sauer ◽

Y Kobayashi ◽

R Buchert ◽

J Mester ◽

...

Keyword(s):

Prostate Cancer ◽

Detection Rate ◽

Radioguided Surgery ◽

Recurrent Prostate Cancer ◽

Psma Pet ◽

Pet Ct

Download Full-text

Modulation of the multistate folding of designed TPR proteins through intrinsic and extrinsic factors

Protein Science ◽

10.1002/pro.2018 ◽

2012 ◽

Vol 21 (3) ◽

pp. 327-338 ◽

Cited By ~ 19

Author(s):

J. J. Phillips ◽

Y. Javadi ◽

C. Millership ◽

E. R. G. Main

Keyword(s):

Extrinsic Factors ◽

Intrinsic And Extrinsic Factors

Download Full-text

Intrinsic and extrinsic factors that may influence DNA preservation in skeletal remains: A review

Forensic Science International ◽

10.1016/j.forsciint.2021.110859 ◽

2021 ◽

Vol 325 ◽

pp. 110859

Author(s):

Caterina Raffone ◽

Miriam Baeta ◽

Nicole Lambacher ◽

Eva Granizo-Rodríguez ◽

Francisco Etxeberria ◽

...

Keyword(s):

Skeletal Remains ◽

Extrinsic Factors ◽

Dna Preservation ◽

Intrinsic And Extrinsic Factors

Download Full-text

Study protocol for a single-centre non-inferior randomised controlled trial on a novel three-dimensional matrix positioning-based cognitive fusion-targeted biopsy and software-based fusion-targeted biopsy for the detection rate of clinically significant prostate cancer in men without a prior biopsy

BMJ Open ◽

10.1136/bmjopen-2020-041427 ◽

2021 ◽

Vol 11 (2) ◽

pp. e041427

Author(s):

Biming He ◽

Rongbing Li ◽

Dongyang Li ◽

Liqun Huang ◽

Xiaofei Wen ◽

...

Keyword(s):

Prostate Cancer ◽

Detection Rate ◽

Three Dimensional ◽

Multiparametric Mri ◽

Fusion Method ◽

Targeted Biopsy ◽

Cognitive Fusion ◽

Single Centre ◽

Clinically Significant ◽

Randomised Controlled

IntroductionThe classical pathway for diagnosing prostate cancer is systematic 12-core biopsy under the guidance of transrectal ultrasound, which tends to underdiagnose the clinically significant tumour and overdiagnose the insignificant disease. Another pathway named targeted biopsy is using multiparametric MRI to localise the tumour precisely and then obtain the samples from the suspicious lesions. Targeted biopsy, which is mainly divided into cognitive fusion method and software-based fusion method, is getting prevalent for its good performance in detecting significant cancer. However, the preferred targeted biopsy technique in detecting clinically significant prostate cancer between cognitive fusion and software-based fusion is still beyond consensus.Methods and analysisThis trial is a prospective, single-centre, randomised controlled and non-inferiority study in which all men suspicious to have clinically significant prostate cancer are included. This study aims to determine whether a novel three-dimensional matrix positioning cognitive fusion-targeted biopsy is non-inferior to software-based fusion-targeted biopsy in the detection rate of clinically significant cancer in men without a prior biopsy. The main inclusion criteria are men with elevated serum prostate-specific antigen above 4–20 ng/mL or with an abnormal digital rectal examination and have never had a biopsy before. A sample size of 602 participants allowing for a 10% loss will be recruited. All patients will undergo a multiparametric MRI examination, and those who fail to be found with a suspicious lesion, with the anticipation of half of the total number, will be dropped. The remaining participants will be randomly allocated to cognitive fusion-targeted biopsy (n=137) and software-based fusion-targeted biopsy (n=137). The primary outcome is the detection rate of clinically significant prostate cancer for cognitive fusion-targeted biopsy and software-based fusion-targeted biopsy in men without a prior biopsy. The clinically significant prostate cancer will be defined as the International Society of Urological Pathology grade group 2 or higher.Ethics and disseminationEthical approval was obtained from the ethics committee of Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. The results of the study will be disseminated and published in international peer-reviewed journals.Trial registration numberClinicalTrials.gov Registry (NCT04271527).

Download Full-text